Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor rejection

por Hartmann, Ann-Kathrin, Bartneck, Joschka, Pielenhofer, Jonas, Meiser, Sophie Luise, Arnold-Schild, Danielle, Klein, Matthias, Stassen, Michael, Schild, Hansjörg, Muth, Sabine, Probst, Hans Christian, Langguth, Peter, Grabbe, Stephan, Radsak, Markus P.
Publicado 2023

Quality by Design (QbD) Approach for a Nanoparticulate Imiquimod Formulation as an Investigational Medicinal Product

por Pielenhofer, Jonas, Meiser, Sophie Luise, Gogoll, Karsten, Ciciliani, Anna-Maria, Denny, Mark, Klak, Michael, Lang, Berenice M., Staubach, Petra, Grabbe, Stephan, Schild, Hansjörg, Radsak, Markus P., Spahn-Langguth, Hilde, Langguth, Peter
Publicado 2023

Tumor-infiltrating CCR2(+) inflammatory monocytes counteract specific immunotherapy

por Bartneck, Joschka, Hartmann, Ann-Kathrin, Stein, Lara, Arnold-Schild, Danielle, Klein, Matthias, Stassen, Michael, Marini, Federico, Pielenhofer, Jonas, Meiser, Sophie Luise, Langguth, Peter, Mack, Matthias, Muth, Sabine, Probst, Hans-Christian, Schild, Hansjörg, Radsak, Markus Philipp
Publicado 2023